1264221-53-5

Basic information

• Product Name: 9-benzyl 2-(tert-butyl) (9S,17aS)-13-fluoro-10-methyl-6,11-dioxo-3,4,6,7,8,9,10,11,17,17a-decahydropyrazino[2,1-c][1,4,9]benzoxadiazacyclododecine-2,9(1H)-dicarboxylate
• Synonyms: 9-benzyl 2-(tert-butyl) (9S,17aS)-13-fluoro-10-methyl-6,11-dioxo-3,4,6,7,8,9,10,11,17,17a-decahydropyrazino[2,1-c][1,4,9]benzoxadiazacyclododecine-2,9(1H)-dicarboxylate
• CAS NO: 1264221-53-5
• Molecular Weight: 569.63
• Mol File: 1264221-53-5.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 9-benzyl 2-(tert-butyl) (9S,17aS)-13-fluoro-10-methyl-6,11-dioxo-3,4,6,7,8,9,10,11,17,17a-decahydropyrazino[2,1-c][1,4,9]benzoxadiazacyclododecine-2,9(1H)-dicarboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: 9-benzyl 2-(tert-butyl) (9S,17aS)-13-fluoro-10-methyl-6,11-dioxo-3,4,6,7,8,9,10,11,17,17a-decahydropyrazino[2,1-c][1,4,9]benzoxadiazacyclododecine-2,9(1H)-dicarboxylate(1264221-53-5)
• EPA Substance Registry System: 9-benzyl 2-(tert-butyl) (9S,17aS)-13-fluoro-10-methyl-6,11-dioxo-3,4,6,7,8,9,10,11,17,17a-decahydropyrazino[2,1-c][1,4,9]benzoxadiazacyclododecine-2,9(1H)-dicarboxylate(1264221-53-5)

Safety Data

• Hazardous Substances Data: 1264221-53-5(Hazardous Substances Data)

Upstream product

• 1264240-00-7 (S)-5-allyl 1-benzyl 2-(5-fluoro-2-hydroxy-N-methylbenzamido)pentanedioate 
• 1264239-95-3 C₂₅H₂₆FNO₇ 
• 5538-52-3 2-acetoxy-5-fluorobenzoyl chloride 
• 448-40-8 2-acetoxy-5-fluoro benzoic acid 
• 345-16-4 5-fluoro-2-hydroxybenzoic acid 
• 1264239-56-6 (S)-5-allyl 1-benzyl 2-(methylamino)pentanedioate hydrochloride 
• 1264239-51-1 C₂₂H₂₄N₂O₈S 
• 1264239-47-5 C₂₁H₂₂N₂O₈S 
• 100-39-0 benzyl bromide 
• 132245-80-8 C₂₀H₂₇NO₆ 
• 1264239-42-0 C₁₅H₁₉NO₄*ClH 
• 132286-79-4 N-α-(t-butoxycarbonyl)-L-glutamic γ-allyl ester 
• 1264239-38-4 1-allyl 4-tert-butyl (S)-2-(hydroxymethyl)piperazine-1,4-dicarboxylate 
• 1217442-24-4 (S)-tert-butyl 3-(hydroxymethyl)piperazine-1-carboxylate hydrochloride 

Relevant articles and documents

CONFORMATION-LOCKED, SYNTHETIC MACROCYCLIC COMPOUND

PROBLEM TO BE SOLVED: To provide a compound effective for treating: diabetic gastroparesis, and impairment of hypomotility in the gastrointestinal tract such as constipation type irritable bowel syndrome; CNS related disorders such as migraine, schizophre

CONFORMATIONALLY CONSTRAINED, SYNTHETIC MACROCYCLIC COMPOUNDS

PROBLEM TO BE SOLVED: To provide a novel macrocyclic compound showing agonistic or antagonistic activity on a motilin receptor, a serotonin receptor and a prostaglandin F2A receptor. SOLUTION: This invention provides a macrocyclic compound incorporating building blocks A, B and C, represented by formula (I). The compound is useful for the treatment of motility disorders of the gastrointestinal tract, CNS-related disease and ocular hypertension. COPYRIGHT: (C)2015,JPO&INPIT

CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS

Conformationally restricted, spatially defined 12-30 membered macrocyclic ring systems of formulae Ia and Ib are constituted by three distinct molecular parts: Template A, conformation Modulator B and Bridge C. These macrocycles Ia and Ib are readily manufactured by parallel synthesis or combinatorial chemistry in solution or on solid phase. They are designed to interact with a variety of specific biological target classes, examples being the agonistic or antagonistic activity on G-protein coupled receptors (GPCRs), ion channels and signal transduction pathways. In particular, these macrocycles act as antagonists of the motilin receptor, the FP receptor and the purinergic receptors P2Y1, as modulators of the serotonin receptor of subtype 5-HT2B, as blockers of the voltage-gated potassium channel Kv1.3 and as inhibitors of the β-catenin-dependent “canonical” Wnt pathway. Thus they are showing great potential as medicaments for a variety of diseases.